Cargando…
Treatment of Diffuse Large B Cell Lymphoma
Diffuse large B cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma in all countries and all age groups. DLBCL is potentially curable, and the outcome of patients with DLBCL has completely changed with the introduction of therapy involving the monoclonal antibody rituximab in co...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
The Korean Association of Internal Medicine
2012
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3529233/ https://www.ncbi.nlm.nih.gov/pubmed/23269875 http://dx.doi.org/10.3904/kjim.2012.27.4.369 |